Sparc’s Pdp-716 Faces Regulatory Speed Breaker As Ocuvex Gets Complete Response Letter from U.S. FDA

Nikunj Parikh May 19, 2026 360 Views

Sun Pharma Advanced Research Company has disclosed that its licensing partner, Ocuvex Therapeutics Inc., has received a Complete Response Letter from the US Food and Drug Administration for the PDP-716 New Drug Application. The setback is tied solely to inspection findings at the finished product manufacturing facility, with no other deficiencies cited on the NDA itself.

Sun Pharma Advanced Research Company (SPARC) informed the stock exchanges under SEBI’s disclosure norms that the US FDA has completed its review and issued a Complete Response Letter on PDP-716, an ophthalmology candidate licensed to Ocuvex Therapeutics. SPARC clarified that the FDA’s concerns are confined to the manufacturing site, and that no clinical, non-clinical or product-specific issues have been raised on the application.

Regulatory Feedback And Manufacturing Focus

According to the company’s intimation, the Complete Response Letter stems from inspection observations at the finished product manufacturing facility supporting PDP-716. The communication underscores that the FDA has not questioned the data submitted in the NDA, implying that addressing the facility-related findings could clear the path for a potential re-submission. This keeps the underlying asset scientifically intact while shifting near-term focus to remediation and compliance actions by the manufacturer.

Next Steps For Sparc And Ocuvex

While SPARC has not detailed timelines, the usual next steps after such a letter involve Ocuvex and the manufacturing partner working on corrective and preventive measures, responding formally to the agency and, where required, supporting re-inspection. For SPARC, the update is an important regulatory milestone disclosure rather than a termination of the PDP-716 program, and the company has positioned the information as part of routine market communication.

Key highlights

Ocuvex Therapeutics receives Complete Response Letter from US FDA for PDP-716 NDA
Reason for CRL limited to inspection findings at finished product manufacturing facility
No additional issues raised on PDP-716 data package or NDA contents
SPARC communicates update under SEBI Regulation 30 disclosure requirements
Remedial actions at the manufacturing site likely to drive future regulatory path